MX2022011712A - Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. - Google Patents
Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.Info
- Publication number
- MX2022011712A MX2022011712A MX2022011712A MX2022011712A MX2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A
- Authority
- MX
- Mexico
- Prior art keywords
- mrgpr
- mas
- modulators
- methods
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical group C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 abstract 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical group C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan en general métodos para modular el MRGPR X4, o para tratar una condición dependiente del MRGPR X4 de manera más específica, al poner en contacto el MRGPR X4 o administrar a un sujeto necesitado de los mismos, respectivamente, una cantidad efectiva de un compuesto que tiene la estructura de la Fórmula (I): (ver Fórmula) o un isómero, racemato, hidrato, solvato, isótopo o sal farmacéuticamente aceptable del mismo, en donde m, n, p, t, A, B, Z, R1, R2 y R3 son como se define en este documento. También se proporcionan composiciones farmacéuticas que contienen estos compuestos, así como también los compuestos mismos. Los moduladores de la proteína G relacionada con Mas (MRGPR) X4, son en particular isoindolinonas e isoquinolinonas sustituidas en el anillo carbocíclico. Los compuestos son útiles para tratar condiciones asociadas con la comezón, condiciones asociadas con el dolor o un trastorno autoinmune.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063011964P | 2020-04-17 | 2020-04-17 | |
PCT/US2021/027477 WO2021211839A1 (en) | 2020-04-17 | 2021-04-15 | Modulators of mas-related g-protein receptor x4 and related products and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011712A true MX2022011712A (es) | 2022-10-07 |
Family
ID=75787327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011712A MX2022011712A (es) | 2020-04-17 | 2021-04-15 | Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11787767B2 (es) |
EP (1) | EP4135691A1 (es) |
JP (1) | JP2023523545A (es) |
KR (1) | KR20230004493A (es) |
CN (1) | CN115397412A (es) |
AU (1) | AU2021255966A1 (es) |
BR (1) | BR112022018001A2 (es) |
CA (1) | CA3170064A1 (es) |
IL (1) | IL297139A (es) |
MX (1) | MX2022011712A (es) |
WO (1) | WO2021211839A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023236920A1 (en) * | 2022-06-07 | 2023-12-14 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
WO2024083210A1 (en) * | 2022-10-21 | 2024-04-25 | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | Compounds, compositions and methods thereof |
WO2024098210A1 (zh) * | 2022-11-07 | 2024-05-16 | 深圳博瑞医药科技有限公司 | 一种芳基羧酸类化合物及其制备Mrgpr X4抑制剂的用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
HUP9902166A3 (en) * | 1996-06-17 | 2001-01-29 | Smithkline Beecham Plc | Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds |
WO2001049289A1 (en) | 1999-12-31 | 2001-07-12 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
AU2001275085A1 (en) * | 2000-06-01 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Methods, compounds and compositions for treating gout |
CA2672903C (en) * | 2006-12-20 | 2012-10-23 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
CA2681633C (en) * | 2007-03-20 | 2018-01-09 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
US10383868B2 (en) * | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases |
CN107033087B (zh) * | 2016-02-04 | 2020-09-04 | 西华大学 | 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途 |
WO2017133258A1 (zh) * | 2016-02-04 | 2017-08-10 | 西华大学 | 1h-吲唑类衍生物及其作为ido抑制剂的用途 |
MX2018009870A (es) * | 2016-02-15 | 2018-11-29 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Inhibidores de taf1 para la terapia del cancer. |
CN108689937B (zh) * | 2017-04-10 | 2021-09-17 | 西华大学 | 吲唑类化合物及其在制备ido抑制剂类药物上的用途 |
IL271889B2 (en) * | 2017-07-10 | 2023-03-01 | Celgene Corp | Antisplit compounds and methods of their use |
WO2019147783A1 (en) | 2018-01-25 | 2019-08-01 | Dana-Farber Cancer Institute, Inc. | Sulfonamide derivatives for protein degradation |
KR102114389B1 (ko) * | 2018-05-02 | 2020-05-25 | 이화여자대학교 산학협력단 | 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN108863892B (zh) * | 2018-07-04 | 2022-04-05 | 温州医科大学 | 一种含酰胺结构的没食子酸甲酯类似物及应用 |
CN110903224A (zh) * | 2018-09-18 | 2020-03-24 | 复旦大学 | 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途 |
JP2022529615A (ja) * | 2019-03-28 | 2022-06-23 | エサイエント ファーマシューティカルズ,インコーポレイティド | Mas関連gタンパク質受容体x4のモジュレーターおよび関連製品ならびに方法 |
WO2021013163A1 (en) * | 2019-07-23 | 2021-01-28 | Taipei Medical University | Histone deacetylase 6 inhibitors and method for treating neuropathic pain |
-
2021
- 2021-04-15 MX MX2022011712A patent/MX2022011712A/es unknown
- 2021-04-15 EP EP21723580.3A patent/EP4135691A1/en active Pending
- 2021-04-15 WO PCT/US2021/027477 patent/WO2021211839A1/en active Application Filing
- 2021-04-15 IL IL297139A patent/IL297139A/en unknown
- 2021-04-15 CN CN202180028815.9A patent/CN115397412A/zh active Pending
- 2021-04-15 US US17/231,834 patent/US11787767B2/en active Active
- 2021-04-15 AU AU2021255966A patent/AU2021255966A1/en active Pending
- 2021-04-15 JP JP2022562471A patent/JP2023523545A/ja active Pending
- 2021-04-15 BR BR112022018001A patent/BR112022018001A2/pt not_active Application Discontinuation
- 2021-04-15 KR KR1020227035933A patent/KR20230004493A/ko unknown
- 2021-04-15 CA CA3170064A patent/CA3170064A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115397412A (zh) | 2022-11-25 |
EP4135691A1 (en) | 2023-02-22 |
IL297139A (en) | 2022-12-01 |
KR20230004493A (ko) | 2023-01-06 |
AU2021255966A1 (en) | 2022-11-17 |
WO2021211839A1 (en) | 2021-10-21 |
CA3170064A1 (en) | 2021-10-21 |
US11787767B2 (en) | 2023-10-17 |
US20210340106A1 (en) | 2021-11-04 |
BR112022018001A2 (pt) | 2022-11-08 |
JP2023523545A (ja) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011712A (es) | Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
MX2021011647A (es) | Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
EA202091930A1 (ru) | Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления | |
CR20200588A (es) | Compuestos novedosos | |
EA201991403A1 (ru) | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
ZA202007688B (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods, and uses thereof | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
WO2022061008A3 (en) | Modulators of mas-related g-protein receptor x4 and related products and methods | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
AU2013301914A8 (en) | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR gamma | |
MX344701B (es) | Derivados de pirrol como moduladores de nachr alfa 7. | |
CR20190567A (es) | Derivados de indol n-sustituidos | |
BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
BR112023022050A2 (pt) | Agonistas do receptor de orexina e usos destes | |
NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
PH12021550549A1 (en) | Dp antagonist | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
MX2023003476A (es) | Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados. | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
ZA202206266B (en) | Pd-l1 antagonist compound | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis |